Related Experiment Videos
Interactions between 11beta-hydroxysteroid dehydrogenase and COX-2 in kidney
Bing Yao1, Raymond C Harris, Ming-Zhi Zhang
1George O'Brien Center for Kidney and Urologic Diseases and Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37232-4794, USA.
This study explores how two proteins, 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2) and cyclooxygenase-2 (COX-2), interact in the kidney to influence blood pressure. In some people, a deficiency in 11betaHSD2 leads to a condition called apparent mineralocorticoid excess (SAME), which causes high blood pressure. The researchers found that when 11betaHSD2 is blocked, COX-2 levels in the kidney change, and this seems to affect how high blood pressure develops. They also looked at how this interaction changes with age and found that young rats have different COX-2 patterns than adults. These results suggest that COX-2 may help modulate blood pressure in people with 11betaHSD2 deficiency.
Area of Science:
- Renal physiology
- Endocrinology
- Hypertension research
Background:
Salt-sensitive hypertension remains poorly understood in some genetic contexts. Prior research has shown that mineralocorticoid receptor (MR) activation by cortisol leads to sodium retention. It was already known that 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2) normally inactivates cortisol in the kidney. However, no prior work had resolved how COX-2 expression might interact with this pathway. This gap motivated an investigation into whether COX-2 could modulate hypertension in 11betaHSD2 deficiency. The urinary concentrating defect in neonates suggests immature COX-2 regulation. That uncertainty drove the need to study developmental changes in COX-2 expression. No prior work had resolved the role of COX-2 in 11betaHSD2-deficient rats. This uncertainty prompted the current study.
Purpose Of The Study:
The aim was to determine whether COX-2 contributes to hypertension in 11betaHSD2 deficiency. Researchers focused on renal medullary and cortical COX-2 expression patterns. They wanted to test if COX-2 inhibition could alter blood pressure in these models. The specific problem addressed was the lack of clarity on COX-2's role in SAME. The motivation came from the known link between MR activation and sodium retention. Researchers also sought to examine developmental differences in COX-2 regulation. The study aimed to clarify whether this interaction is age-dependent. They wanted to establish if COX-2 expression is modulated by MR activation.
Main Methods:
The study used rats with 11betaHSD2 inhibition and compared them to controls. Researchers measured COX-2 expression in renal medulla and cortex. They tested the effects of COX-1 and COX-2 inhibitors on blood pressure. Animals were divided into groups based on salt intake and age. Suckling, weaning, and adult rats were all included. Expression levels were analyzed using molecular techniques. Blood pressure was monitored under high-salt conditions. The experimental design allowed for age-specific comparisons.
Main Results:
11betaHSD2 inhibition increased medullary COX-2 expression in adult rats. It also decreased cortical COX-2 expression in the same group. High-salt-treated rats with 11betaHSD2 inhibition developed hypertension. COX-2 inhibition further raised blood pressure in these animals. COX-1 inhibition had no effect on blood pressure in any group. In weaning rats, 11betaHSD2 inhibition activated MRs and altered COX-2. Suckling rats had low medullary COX-2, consistent with a concentrating defect. 11betaHSD2 inhibition had no effect on COX-2 in neonates.
Conclusions:
The data suggest that COX-2 modulates hypertension in 11betaHSD2 deficiency. The study shows that 11betaHSD2 prevents glucocorticoid access to MRs. This interaction appears to regulate renal COX-2 expression during development. COX-2 inhibition worsened hypertension in 11betaHSD2-deficient rats. The findings support a role for COX-2 in the pathophysiology of SAME. The effect was absent in neonates due to low corticosterone levels. These results imply that COX-2 activity is developmentally regulated. The authors propose that COX-2 may serve as a compensatory mechanism.
Frequently Asked Questions
11betaHSD2 normally inactivates cortisol. In its absence, cortisol activates MRs, causing sodium retention and high blood pressure.
COX-2 inhibition further increases blood pressure in high-salt-treated 11betaHSD2-deficient rats.
Suckling rats have low medullary COX-2, which may explain their urinary concentrating defect.
COX-2 increases in the renal medulla and decreases in the cortex in 11betaHSD2-deficient adults.
COX-1 inhibition had no effect on blood pressure in either control or experimental animals.
The authors propose that 11betaHSD2 regulates COX-2 by preventing glucocorticoid access to MRs.